Neuropein 1g (Meropenem Hydrate)

Adult administration

As meropenem hydrate, administer 0.5 to 1 g (potency) per day divided into 2 to 3 doses by intravenous infusion over more than 30 minutes. For suspected infections in patients with pathogenic pneumonia, peritonitis, and neutropenia, administer 1 g (potency) by intravenous infusion every 8 hours. For cystic fibrosis and meningitis, administer 2 g (potency) by intravenous infusion every 8 hours.

Child administration

For bacterial meningitis in children over 3 months of age, administration is by intravenous drip at a dosage of 40 mg per kg of body weight every 8 hours over more than 30 minutes, depending on the pathogen's sensitivity and the patient's condition.

This medication should not be given to patients who have previously experienced shock due to this drug. Additionally, patients taking valproate sodium should be careful as this drug can lower the blood concentration of valproate, potentially leading to a recurrence of epileptic seizures. It should also be avoided in patients with hypersensitivity to this drug or any of its components, and in those with a history of severe allergic reactions to other carbapenems or beta-lactam antibiotics. Patients with an allergic disposition or those who have bronchial asthma, rashes, etc. should use this medication cautiously. Patients with impaired kidney function may experience prolonged retention of the drug in the body, leading to central nervous system side effects, so the dosage may need to be reduced or the dosing interval extended. Caution is also advised for patients with epilepsy, central nervous system disorders, or severe liver dysfunction. Elderly patients may experience side effects due to decreased body function and need careful monitoring. Patients who have difficulty with oral intake, those in poor nutritional status, and infants under 3 months also require special observation when using this medication. While using this medication, serious allergic reactions such as shock and anaphylaxis may occur infrequently, so patient status should be closely monitored. If symptoms of hypersensitivity such as rash, urticaria, or itching occur, administration should be stopped immediately, and appropriate treatment must be taken. Regular blood tests are necessary as symptoms such as leukopenia, anemia, and platelet anomalies may be detected. Symptoms of liver disease such as liver dysfunction, acute hepatitis, and jaundice should be carefully monitored. Regular kidney function tests should be performed as impaired kidney function or acute renal failure may occur. In the gastrointestinal system, severe diarrhea or abdominal pain, as well as severe colitis may occur, and symptoms should be monitored closely. Central nervous system side effects such as seizures, altered consciousness, etc., require immediate action if abnormal symptoms are noted. Respiratory system issues, severe skin reactions, stomatitis, and candidiasis may also occur, necessitating observation. Various side effects such as symptoms of vitamin deficiency, cardiovascular anomalies, and neurological symptoms have been reported, so ongoing assessment of the patient's condition is essential. To prevent the development of resistant bacteria, it is important to confirm susceptibility and administer the minimum necessary duration. If administration begins without confirming susceptibility, the susceptibility should be tested within 3 days to determine if appropriate treatment is warranted. Since there is a risk of shock, it is advisable to conduct sufficient medical interviews and skin tests before administration, and to monitor the patient in a stable condition after administration. With long-term use, vigilance for the occurrence of side effects such as rashes and liver function anomalies is crucial, and if treatment exceeds 7 days, a clear rationale must be established. Liver function tests must be performed if treatment exceeds 1 week. It is essential to confirm any history of hypersensitivity to beta-lactam drugs such as penicillin and cephalosporins prior to administration. Symptoms such as headaches and mental confusion may occur during the use of this medication, thus caution is required when driving or operating machinery. If muscle pains, weakness, or dark urine occur, this could signal rhabdomyolysis, and immediate notification of healthcare personnel is necessary. This medication may interact with certain drugs, so caution is required when used in conjunction with probenecid, antiepileptic drugs, contraceptives, warfarin, etc. Particularly, close monitoring of blood coagulation tests (INR) is needed when administered alongside warfarin. Women who are pregnant or of childbearing age must carefully consider the risks and benefits of administering this medication, and breastfeeding should be avoided if using it. The safety and efficacy for infants under 3 months have not been established, therefore caution should be exercised in their use. Elderly individuals, due to declining bodily functions, are at higher risk of experiencing side effects, requiring careful observation and adjustments to dosage and intervals. This medication should be used quickly after reconstitution, and if stored, must be used within 6 hours at room temperature or within 24 hours if refrigerated. It is only for intravenous use, and color changes in the solution do not affect its efficacy.

Serious side effects

Shock, anaphylactic reactions, severe allergic reactions, serious skin adverse reactions (toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS syndrome, erythema multiforme, acute generalized exanthematous pustulosis), severe renal impairment (acute renal failure), severe colitis such as membranous colitis, seizures, altered consciousness, central nervous system symptoms, asthma, dyspnea, respiratory anomalies, jaundice, liver dysfunction, fulminant hepatitis, urticaria,

Mild side effects

• Oral abnormalities
• wheezing
• dizziness
• diarrhea
• tinnitus
• sweating
• rash
• feeling of warmth
• erythema
• itching

This medication should be stored in a sealed container to prevent exposure to air and kept at a temperature between 1 to 30 degrees Celsius. Avoid warm or excessively cold areas, and maintain a stable temperature to ensure the drug's effectiveness.

Appearance

A colorless transparent vial filled with crystalline powder that is white to light yellow.

Package unit

10 vials